
Todd C. Lee
@drtoddlee
Clinician-scientist at McGill
Fellow of the Infectious Diseases Society of America.
Co-inventor of medsafer.org
Immortal-time Lord.
Legacy verified.
ID: 4260929247
http://www.drtoddlee.com 24-11-2015 00:31:31
44,44K Tweet
14,14K Followers
366 Following

🧂Hyponatremia is a common the ICU, but correcting it smoothly & safely can be challenging. 🧠Rapid correction risks serious complications like ODS/CPM 📈That's why I built NaPathway - a free app - to help clinicians monitor sodium correction Try it criticalcaretime.com/tools/hyponatr… 🧵

How much evidence is needed to revise established clinical practices? and, can data alone truly catalyze such shifts? Our 🆕🔥 Article Clinical Infectious Diseases super 🌟s McPhillips MD & Brad Spellberg Others Practicing With Intent: How to Teach an Old Dogma New Tricks academic.oup.com/cid/article/do…


Did it make sense for an observational study to suggest that cefepime had a markedly reduced mortality vs piperacillin-tazobactam? Why did instrumental variable analysis lead the data astray? Always fun to write with peeps like Gus Hamilton Guillaume Butler-Laporte academic.oup.com/cid/advance-ar…

Practicing With Intent: How to Teach an Old Dogma New Tricks It was an honor to stand beside this team of Martians and Venusians McPhillips MD Brad Spellberg Emily McDonald Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 Todd C. Lee Steven Tong & many others academic.oup.com/cid/article/do…

Meta-analysis: Prescribing interventions targeting potentially inappropriate medications were safe and associated with reductions in the number of medications prescribed. ja.ma/44slwE1 Todd C. Lee


Half year of running complete Accomplished: PRs: marathon 2:56:11 3k 10:15 Cooper 3507m 2080km run Recovered piriformis syndrome New battle: right lateral ankle tendonitis Plans for second half of year: 1mi PR if possible 5km PR if possible 10km PR HM PR Valueinvestor411



Why do 80% of CT scans this week report bilateral pyelonephritis.... Including many people who don't have pyelonephritis Matthew P. Cheng